Anzeige
Meldung des Tages: 25 % Ölpreisschock am Wochenende – profitiert jetzt dieser Effizienz-Hidden-Champion?

Galmed Pharmaceuticals News

Aktie
WKN:  A1XFUX ISIN:  IL0011313900 US-Symbol:  GLMD Branche:  Biotechnologie Land:  Israel
0,7165 $
+0,00 $
0,00%
0,6161 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
4,03 Mio. €
Streubesitz
98,04%
KGV
-0,71
Index-Zuordnung
-

Galmed Pharmaceuticals News

30.01.26 - PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
08.12.25 - PR Newswire
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Announces Acceptance of a Late-​Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR Newswire
04.12.25 - PR Newswire
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PR Newswire
01.12.25 - PR Newswire
Galmed Issues CEO Letter to Shareholders
Galmed Issues CEO Letter to Shareholders PR Newswire
26.11.25 - PR Newswire
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
18.11.25 - PR Newswire
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire
17.11.25 - PR Newswire
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo ...
28.08.25 - PR Newswire
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
25.08.25 - PR Newswire
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value PR Newswire
27.05.25 - PR Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-​Billion-Dollar Expansion Potential Beyond NASH PR Newswire
22.05.25 - PR Newswire
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
13.05.25 - PR Newswire
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Galmed Reports Significant Anti-​Fibrotic Effects of Aramchol in PSC Models PR Newswire
06.05.25 - PR Newswire
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models PR Newswire
28.04.25 - PR Newswire
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation PR Newswire
17.04.25 - PR Newswire
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers PR Newswire
15.04.25 - PR Newswire
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor PR Newswire
10.04.25 - PR Newswire
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor PR Newswire
02.04.25 - PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 PR Newswire
20.03.25 - PR Newswire
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy PR Newswire

Newssuche

Videos

newspaper
04.03.26 -6,24%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »